Factor VIIa-CTP

Drug Profile

Factor VIIa-CTP

Alternative Names: FVII-CTP; MOD-5014; MOD-5017

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator PROLOR Biotech
  • Developer OPKO Health
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Factor VIIa stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilia

Most Recent Events

  • 27 Sep 2016 Opko plans a phase I trial in Healthy male volunteers in Israel (NCT02919800)
  • 04 Mar 2016 9192079 - checked against MR, no relevant updates
  • 29 Feb 2016 OPKO Health initiates a phase IIa trial for Haemophilia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top